Ernst de Bruijn

825 citations

22 papers · 561 indexed · h-index 14

Oncology top 10%
Pulmonary and Respiratory Medicine
Pediatrics, Perinatology and Child Health top 10%
Molecular Biology
Epidemiology

Co-authors: Liesbeth Heyns René Verbesselt Kristel Van Calsteren Frédéric Amant Rieta Van Bree Jan de Hoon Daniel Chai Gert De Boeck
Topics: Hepatocellular Carcinoma Treatment and Prognosis (4 papers)Cancer Research and Treatments (3 papers)Cancer Risks and Factors (3 papers)
Cited by: Oncology Biotechnology Gastroenterology
Journals: Clinical Cancer Research British Journal of Cancer Annals of Oncology
Partner nations: Belgium Netherlands Switzerland

In The Last Decade

Ernst de Bruijn

21 papers receiving 542 citations

Peers

Countries citing papers authored by Ernst de Bruijn

Since Specialization

Citations

This map shows the geographic impact of Ernst de Bruijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernst de Bruijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernst de Bruijn more than expected).

Fields of papers citing papers by Ernst de Bruijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernst de Bruijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernst de Bruijn. The network helps show where Ernst de Bruijn may publish in the future.

Co-authorship network of co-authors of Ernst de Bruijn

This figure shows the co-authorship network connecting the top 25 collaborators of Ernst de Bruijn. A scholar is included among the top collaborators of Ernst de Bruijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernst de Bruijn. Ernst de Bruijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter Phase II Clinical Trial of Isolated Lung Perfusion in Patients With Lung Metastases 2019 ·The Annals of Thoracic Surgery ·(unknown),Michel I.M. Versteegh,Thomas J. van Brakel,Jerry Braun,Bart Van de Putte,Alexander P.W.M. Maat,(unknown),Inez Rodrigus,(unknown),Filip Lardon,Ernst de Bruijn,Gunther Guetens,Gert De Boeck,Jan F. Gielis,Patrick Lauwers,(unknown),Jeroen Hendriks,Paul Van Schil	15
2	Analysis of novel melphalan hydrolysis products formed under isolated lung perfusion conditions using liquid chromatography/tandem mass spectrometry 2013 ·Rapid Communications in Mass Spectrometry ·Jasper Boschmans,Ernst de Bruijn,Paul Van Schil,Filip Lemière	11
3	Substantial Variation in Transplacental Transfer of Chemotherapeutic Agents in a Mouse Model 2010 ·Reproductive Sciences ·Kristel Van Calsteren,René Verbesselt,Rieta Van Bree,Liesbeth Heyns,Ernst de Bruijn,Jan de Hoon,Frédéric Amant	43
4	Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study 2010 ·Acta Obstetricia Et Gynecologica Scandinavica ·Kristel Van Calsteren,René Verbesselt,Nelleke Ottevanger,M Halaška,Liesbeth Heyns,Rieta Van Bree,Ernst de Bruijn,Daniel Chai,Michel Delforge,Lucien Noens,Vincent Renard,Els O. Witteveen,Lukáš Rob,Jan de Hoon,Frédéric Amant	81
5	Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. 2010 ·PubMed ·Kristel Van Calsteren,René Verbesselt,Roland Devlieger,Luc De Catte,Daniel Chai,Rieta Van Bree,Liesbeth Heyns,Jos H. Beijnen,(unknown),Ernst de Bruijn,Jan de Hoon,Frédéric Amant	81
6	Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial 2007 ·Journal of Surgical Oncology ·(unknown),Jeroen Hendriks,Wim Jan van Boven,Catherijne A. J. Knibbe,Bart Van de Putte,Bernard Stockman,Ernst de Bruijn,Jan B. Vermorken,Paul Van Schil,Franz M.N.H. Schramel	12
7	Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines 2006 ·Pharmacology ·Hans Prenen,Gunther Guetens,Gert De Boeck,Maria Dêbiec‐Rychter,Paul W. Manley,Patrick Schöffski,Allan T. van Oosterom,Ernst de Bruijn	55
8	Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR 2005 ·Clinical Cancer Research ·Josep Tabernero,Patrick Schöffski,Federico Rojo,Ernst de Bruijn,(unknown),Herlinde Dumez,Teresa Macarulla,Hans Prenen,E. Casado,Gunther Guetens,(unknown),(unknown),(unknown),(unknown),Santiago Ramón y Cajal,(unknown),(unknown),A. Van Oosterom,José Baselga	4
9	Imatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma Membrane 2005 ·American journal of biochemistry & biotechnology ·Hans Prenen,Cristiana Stefan,Bart Landuyt,Peter Vermaelen,(unknown),Mathieu Bollen,Sigrid Stroobants,Ernst de Bruijn,Luc Mortelmans,Raf Sciot,Patrick Schöffski,A. van Oosterom	17
10	Isolated Lung Perfusion With Melphalan for Resectable Lung Metastases: A Phase I Clinical Trial 2004 ·The Annals of Thoracic Surgery ·Jeroen Hendriks,Marco J.J.H. Grootenboers,Franz M.N.H. Schramel,Wim Jan van Boven,Bernard Stockman,Cornelis A. Seldenrijk,(unknown),Catherijne A. J. Knibbe,P. H. Th. J. Slee,Ernst de Bruijn,(unknown),(unknown),Jan B. Vermorken,Bart Van de Putte,(unknown),Eric Van Marck,Paul Van Schil	48
11	Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours 2003 ·British Journal of Cancer ·Tom Dresselaers,Jan Theys,Sandra Nuyts,Bradly G. Wouters,Ernst de Bruijn,Jozef Anné,Philippe Lambin,Paul Van Hecke,Willy Landuyt	29
12	Pharmacokinetics after pulmonary artery perfusion with gemcitabine 2003 ·The Annals of Thoracic Surgery ·Bart P. van Putte,Jeroen Hendriks,(unknown),Bea Pauwels,Gert De Boeck,Gunther Guetens,Ernst de Bruijn,Paul Van Schil	14
13	Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes 2001 ·Cancer Investigation ·Willy Landuyt,Jan Theys,Sandra Nuyts,M. Drijkoningen,Jack Fowler,(unknown),Sandra Liekens,Johan Neyts,Ernst de Bruijn,Jozef Anné,Philippe Lambin	2
14	Pharmacokinetics of Ifosfamide Are Changed by Combination With Docetaxel 2000 ·American Journal of Clinical Oncology ·D. Schrijvers,L. Pronk,Martin Highley,René Bruno,(unknown),Ernst de Bruijn,A.T. van Oosterom,Jaap Verweij	17
15	KW-2149-induced pulmonary toxicity is not prevented by corticosteroids 1999 ·Anti-Cancer Drugs ·D. Schrijvers,G. Catimel,Martin Highley,(unknown),Luc Dirix,Ernst de Bruijn,J.P. Droz,(unknown)	7
16	Vascular endothelial growth factor (VEGF): Plasma is the place to be 1998 ·Annals of Oncology ·Wim Wynendaele,Rita Derua,Marc Hoylaerts,Adam Pawinski,Etienne Waelkens,Ernst de Bruijn,Wilfried Merlevede,Robert Paridaens,A. van Oosterom	2
17	Colonisation ofClostridiumin the body is restricted to hypoxic and necrotic areas of tumours 1998 ·Anaerobe ·Philippe Lambin,Jan Theys,Willy Landuyt,Paul F.J.W. Rijken,Albert van der Kogel,E. van der Schueren,R.J. Hodgkiss,Jack Fowler,Sandra Nuyts,Ernst de Bruijn,Lieve Van Mellaert,Jozef Anné	73
18	Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion 1995 ·Investigational New Drugs ·Luc Dirix,G. Catimel,René Verdonk,Ernst de Bruijn,Brigitte Tranchand,C Ardiet,A. van Oosterom	2
19	Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149 1995 ·Anti-Cancer Drugs ·Luc Dirix,G. Catimel,(unknown),A. Prové,Dirk Schrijvers,(unknown),Ernst de Bruijn,C Ardiet,(unknown),A Dumortier,(unknown),A. van Oosterom	13
20	Multidrug Resistance in Rat Colon Carcinoma Cell Lines CC531, CC531^mdr+ and CC531^rev 1993 ·Japanese Journal of Cancer Research ·E. Gheuens,(unknown),Hilde Elst,Alexander M.M. Eggermont,A. van Oosterom,Ernst de Bruijn	13

About Ernst de Bruijn

Ernst de Bruijn is a scholar working on Toxicology, Hepatology and Gastroenterology, having authored 22 papers that have together received 561 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cancer Research and Treatments (3 papers) and Cancer Risks and Factors (3 papers). The work is most often cited by research in Oncology (281 citations), Biotechnology (78 citations) and Gastroenterology (48 citations). Ernst de Bruijn has collaborated with scholars based in Belgium, Netherlands and Switzerland. Frequent co-authors include Liesbeth Heyns, René Verbesselt, Kristel Van Calsteren, Frédéric Amant, Rieta Van Bree, Jan de Hoon, Daniel Chai, Gert De Boeck, Gunther Guetens and Patrick Schöffski. Their work appears in journals such as Clinical Cancer Research, British Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact